Interpretation on circumscribed astrocytic gliomas in the 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition)

doi:10.3969/j.issn.1672-6731.2021.09.010

Abstract

Abstract:

In the 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition), the term "circumscribed" was used to classify astrocytic gliomas with localized growth characteristics. So far, the descriptions of "diffuse" and "circumscribed", which define the growth mode, have been applied to the classification of gliomas. This paper interprets the content of circumscribed astrocytic gliomas in the new edition tumors classification, introduces the definitions and clinical characteristics of high-grade astrocytoma with piloid features and astroblastoma, MN1-altered, and analyzes the value and significance of molecular markers and gene changes in the diagnosis and treatment of circumscribed astrocytic gliomas.

Key words: Glioma, Astrocytes, Guidelines, World Health Organization, Review

摘要：

2021年世界卫生组织中枢神经系统肿瘤分类（第五版，简称新版肿瘤分类）将“局限性（circumscribed）”一词用于具有局限性生长特性的星形细胞胶质瘤的分类，至此，“弥漫性（diffuse）”和“局限性”这种定义生长方式的描述应用于胶质瘤的命名。本文解读新版肿瘤分类的局限性星形细胞瘤，介绍新增的有毛细胞样特征的高级别星形细胞瘤和星形母细胞瘤，MN1变异型相关定义和临床特征，并总结分子生物学标志物和分子病理学改变在局限性星形细胞胶质瘤诊断与治疗中的价值。

关键词: 神经胶质瘤, 星形细胞, 指南, 世界卫生组织, 综述

LI Fei, SHI Yu, YAO Xiao-hong, FENG Hua. Interpretation on circumscribed astrocytic gliomas in the 2021 WHO Classification of Tumors of the Central Nervous System (fifth edition)[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(9): 804-808.

李飞, 时雨, 姚小红, 冯华. 2021年世界卫生组织中枢神经系统肿瘤分类（第五版）局限性星形细胞胶质瘤分类解读[J]. 中国现代神经疾病杂志, 2021, 21(9): 804-808.

/ / Recommend / Download Citations

URL: http://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2021.09.010

http://journal11.magtechjournal.com/cjcnn/EN/Y2021/V21/I9/804

References

[1] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System:a summary[J]. Acta Neuropathol, 2016, 131:803-820.
[2] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System:a summary[J]. Neuro Oncol, 2021, 23:1231-1251.
[3] Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, Giannini C, Haberler C, Hawkins C, Komori T, Kros JM, Ng HK, Orr BA, Park SH, Paulus W, Perry A, Pietsch T, Reifenberger G, Rosenblum M, Rous B, Sahm F, Sarkar C, Solomon DA, Tabori U, van den Bent MJ, von Deimling A, Weller M, White VA, Ellison DW. cIMPACT-NOW update 6:new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading[J]. Brain Pathol, 2020, 30:844-856.
[4] Kulac I, Tihan T. Pilomyxoid astrocytomas:a short review[J]. Brain Tumor Pathol, 2019, 36:52-55.
[5] Yang B, Yang C, Du J, Fang J, Li G, Wang S, Xu Y. Chordoid glioma:an entity occurring not exclusively in the third ventricle[J]. Neurosurg Rev, 2020, 43:1315-1322.
[6] Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE, Koelsche C, Huang K, Wefers AK, Hovestadt V, Sill M, Gramatzki D, Felsberg J, Reifenberger G, Koch A, Thomale UW, Becker A, Hans VH, Prinz M, Staszewski O, Acker T, Dohmen H, Hartmann C, Mueller W, Tuffaha MSA, Paulus W, Heß K, Brokinkel B, Schittenhelm J, Monoranu CM, Kessler AF, Loehr M, Buslei R, Deckert M, Mawrin C, Kohlhof P, Hewer E, Olar A, Rodriguez FJ, Giannini C, NageswaraRao AA, Tabori U, Nunes NM, Weller M, Pohl U, Jaunmuktane Z, Brandner S, Unterberg A, Hänggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Jones DTW, von Deimling A, Capper D. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations[J]. Acta Neuropathol, 2018, 136:273-291.
[7] Reinhardt A, Stichel D, Schrimpf D, Koelsche C, Wefers AK, Ebrahimi A, Sievers P, Huang K, Casalini MB, Fernández-Klett F, Suwala A, Weller M, Gramatzki D, Felsberg J, Reifenberger G, Becker A, Hans VH, Prinz M, Staszewski O, Acker T, Dohmen H, Hartmann C, Paulus W, Heß K, Brokinkel B, Schittenhelm J, Buslei R, Deckert M, Mawrin C, Hewer E, Pohl U, Jaunmuktane Z, Brandner S, Unterberg A, Hänggi D, Platten M, Pfister SM, Wick W, Herold-Mende C, Korshunov A, Reuss DE, Sahm F, Jones DTW, Capper D, von Deimling A. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities[J]. Acta Neuropathol Commun, 2019, 7:163.
[8] Salles D, Laviola G, Malinverni ACM, Stávale JN. Pilocytic astrocytoma:a review of general, clinical, and molecular characteristics[J]. J Child Neurol, 2020, 35:852-858.
[9] Mair MJ, Wöhrer A, Furtner J, Simonovska A, Kiesel B, Oberndorfer S, Ungersböck K, Marosi C, Sahm F, Hainfellner JA, Rössler K, Preusser M, Widhalm G, Berghoff AS. Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma[J]. J Neurooncol, 2020, 148:187-198.
[10] Dono A, Lopez-Rivera V, Chandra A, Lewis CT, Abdelkhaleq R, Sheth SA, Ballester LY, Esquenazi Y. Predictors of outcome in pleomorphic xanthoastrocytoma[J]. Neurooncol Pract, 2020, 8:222-229.
[11] Shaikh N, Brahmbhatt N, Kruser TJ, Kam KL, Appin CL, Wadhwani N, Chandler J, Kumthekar P, Lukas RV. Pleomorphic xanthoastrocytoma:a brief review[J]. CNS Oncol, 2019, 8:CNS39.
[12] Jansen AC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D'Amato L, d'Augères GB, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Kingswood JC. Clinical characteristics of subependymal giant cell astrocytoma in tuberous sclerosis complex[J]. Front Neurol, 2019, 10:705.
[13] Godoy LL, Ferreira Alves CAP. Atypical subependymal giant cell astrocytoma and neonatal tuberous sclerosis[J]. Neurology, 2018, 90:570-571.
[14] Yao K, Duan Z, Du Z, Fan X, Qu Y, Zhang M, Wang Y, Liu H, Sun L, Qi X. PRKCA D463H mutation in chordoid glioma of the third ventricle:a cohort of 16 cases, including two cases harboring BRAFV600E mutation[J]. J Neuropathol Exp Neurol, 2020, 79:1183-1192.
[15] Mhatre R, Sugur HS, Nandeesh BN, Chickabasaviah Y, Saini J, Santosh V. MN1 rearrangement in astroblastoma:study of eight cases and review of literature[J]. Brain Tumor Pathol, 2019, 36:112-120.
[16] Chen W, Soon YY, Pratiseyo PD, Sutanto R, Hendriansyah L, Kuick CH, Chang KTE, Tan CL. Central nervous system neuroepithelial tumors with MN1-alteration:an individual patient data meta-analysis of 73 cases[J]. Brain Tumor Pathol, 2020, 37:145-153.
[17] Hirose T, Nobusawa S, Sugiyama K, Amatya VJ, Fujimoto N, Sasaki A, Mikami Y, Kakita A, Tanaka S, Yokoo H. Astroblastoma:a distinct tumor entity characterized by alterations of the X chromosome and MN1 rearrangement[J]. Brain Pathol, 2018, 28:684-694.
[18] Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, Capper D, Figarella-Branger D, Lopes MB, Wick W, van den Bent M. cIMPACT-NOW update 1:Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)[J]. Acta Neuropathol, 2018, 135:481-484.
[19] Lehman NL, Usubalieva A, Lin T, Allen SJ, Tran QT, Mobley BC, McLendon RE, Schniederjan MJ, Georgescu MM, Couce M, Dulai MS, Raisanen JM, Al Abbadi M, Palmer CA, Hattab EM, Orr BA. Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis[J]. Acta Neuropathol Commun, 2019, 7:42.
[20] Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Dalton JD, Mulcahy-Levy J, Foreman N, Karajannis MA, Wang S, Snuderl M, Nageswara Rao A, Giannini C, Kieran M, Ligon KL, Garre ML, Nozza P, Mascelli S, Raso A, Mueller S, Nicolaides T, Silva K, Perbet R, Vasiljevic A, Faure Conter C, Frappaz D, Leary S, Crane C, Chan A, Ng HK, Shi ZF, Mao Y, Finch E, Eisenstat D, Wilson B, Carret AS, Hauser P, Sumerauer D, Krskova L, Larouche V, Fleming A, Zelcer S, Jabado N, Rutka JT, Dirks P, Taylor MD, Chen S, Bartels U, Huang A, Ellison DW, Bouffet E, Hawkins C, Tabori U. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas[J]. J Clin Oncol, 2017, 35:2934-2941.
[21] Rudà R. New developments and new dilemmas in lower-grade gliomas[J]. Neuro Oncol, 2019, 21:828-829.

Please choose a citation manager

Content to export